Basics Editas Medicine, Inc. Editas Medicine Inc is a genome editing company which is engaged in treating patients with genetically defined diseases by correcting disease-causing genes. IPO Date: February 3, 2016 Sector: Healthcare Industry: Biotech Market Cap: $236.24M Activated in VL: True Average Daily Range Avg Daily Range: $0.70 | 3.39% Avg Daily Range (30 D): $0.09 | 3.27% Avg Daily Range (90 D): $0.12 | 3.98% Institutional Daily Volume Avg Daily Volume: 1.29M Avg Daily Volume (30 D): 1.84M Avg Daily Volume (90 D): 2.1M Trade Size Avg Trade Size (Sh.): 111 Avg Trade Size (Sh.) (30 D): 175 Avg Trade Size (Sh.) (90 D): 191 Institutional Trades Total Inst.Trades: 3,812 Avg Inst. Trade: $2.01M Avg Inst. Trade (30 D): $.55M Avg Inst. Trade (90 D): $1.12M Avg Inst. Trade Volume: .1M Avg Inst. Trades (Per Day): 2 Market Closing Trades Avg Closing Trade: $2.78M Avg Closing Trade (30 D): $1.9M Avg Closing Trade (90 D): $1.85M Avg Closing Volume: 159.73K     News Nov 17, 2025 @ 3:00 PM Gene Therapies for Cancer Treatment Market Project... Source: Towards Healthcare Sep 25, 2025 @ 1:15 PM Healthcare Innovation Accelerates as Four Convergi... Source: Prnewswire Sep 2, 2025 @ 10:00 AM Gene Editing Market to Surpass USD 15.46 Billion b... Source: Sns Insider Jun 27, 2025 @ 12:15 PM 2 Beaten-Down Stocks to Avoid Source: Prosper Junior Bakiny Jun 17, 2025 @ 2:07 PM Editas Medicine Is Great. Here's Why You Shouldn't... Source: Dan Victor Financials   TTM Q3 2025 Q2 2025 Basic EPS $-2.38 $-.28 $-.63 Diluted EPS $-2.38 $-.28 $-.63 Revenue $ 46.38M $ 7.54M $ 3.58M Gross Profit $ $ $ Net Income / Loss $ -199.84M $ -25.12M $ -53.24M Operating Income / Loss $ -198.85M $ -24.55M $ -51.54M Cost of Revenue $ $ $ Net Cash Flow $ 68.61M $ 25.9M $ -.15M PE Ratio